Nagoya University scientists develop a machine learning tool to uncover how ALS progresses in patients and offer clues to understand why some patients decline faster than others.

ALS (amyotrophic lateral sclerosis) is a fatal neurodegenerative disease that gradually affects a person's ability to move, speak and breathe. It advances differently in every patient. Now, ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...

There could be new hope for ALS management as a promising drug enters phase 3 clinical trials. ALS is a progressive disease in which the brain loses connection with the muscles, The ALS Association ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. One of the most frustrating parts of amyotrophic lateral ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes the progressive loss of motor neurons, which in most cases leads to respiratory failure within three to five years after ...

Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced that the first participant has been dosed in NeurALS, ...